SYL1801
Age-Related Macular Degeneration (AMD)
Phase 2aActive
Key Facts
About Sylentis
Sylentis is a clinical-stage biotechnology company pioneering RNAi-based therapies for ocular diseases. The company leverages its proprietary SirFinder™ AI-driven platform to design highly specific siRNA compounds, with a pipeline led by tivanisiran for dry eye disease and SYL1801 for age-related macular degeneration (AMD). As a subsidiary of PharmaMar, Sylentis operates with a dual business model, advancing its own therapeutic pipeline while also offering CDMO and partnership services for external RNAi drug development.
View full company profileTherapeutic Areas
Other Age-Related Macular Degeneration (AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed AMD Program | Character Biosciences | Research |
| AMD POC Diagnostic | maintect | Research |
| Biosimilar Ranibizumab | Paras Biopharmaceuticals Finland | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |